Innovative Industrial Properties Stock Earnings Reports

Key points for investors: Innovative Industrial Properties (IIP) reported a solid start to 2026 with Q1 total revenues of $69.0 million and AFFO of $53.4 million ($1.88 per share), in line with the prior quarter. The company highlighted a major regulatory development: the DOJ moved FDA‑approved cannabis products and state‑licensed medical cannabis to Schedule III, which management views as a watershed event expected to improve operator economics (including potential 280E tax relief), access to capital and industry momentum. Operationally, IIP has been active on leasing and portfolio stabilization — year‑to‑date leases and LOIs cover roughly 389k–488k sq. ft across multiple markets, including re‑tenants for former Gold Flora, PharmaCann and 4Front assets. On the life‑science front, IIP has funded $175M of a $270M commitment to IQHQ and sees attractive, accretive deployment opportunities. Capital and liquidity actions are a near‑term focus: the company has raised $128M of gross proceeds YTD (preferred, common equity and a $20M secured loan at 9%) and is pursuing additional secured/unsecured financings (~$130M, including a $56.5M financing at ~8.75% expected to fund imminently) to address an unsecured bond maturity and preserve balance sheet flexibility. Balance sheet metrics remain strong (approx. $177M liquidity as of 3/31, debt service coverage >11x, net debt/adjusted EBITDA ~1.1x). Management cautioned that macro headwinds, inflation and elevated rates persist, financings remain subject to contingencies, and tenant/industry credit risk will continue to require active portfolio management.